The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis
Oncology · 2025
DOI: 10.1159/000547264 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology, 2025. Verfasst von Ryo Sato und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nagoya City University, East Medical Center, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neutrophils, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Atezolizumab plus bevacizumab (ATZ/BEV) is used for the treatment of unresectable hepatocellular carcinoma (u-HCC). However, there are few reports investigating the predictors of whether or not disease control can be achieved for long periods.
Methods
We enrolled 106 u-HCC patients who were treated with ATZ/BEV as the first-line systemic chemotherapy and were evaluated as nonprogressive disease (non-PD) in their initial assessments. They were divided into two groups: patients who had achieved disease control (non-PD) for more than 6 months, Group-L, and patients who had progressed (PD) within 6 months, Group-S. We investigated the predictors of long-term therapeutic efficacy.
Results
Patients in Group-L had significantly lower neutrophil-to-lymphocyte ratios (NLR) (the ratios of NLR at the start of the second course of ATZ/BEV to their pretreatment levels) than Group-S (p = 0.044), and the optimal cutoff value was 1.129. The patients with an NLR ratio
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nagoya City University, East Medical Center, Nagoya, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, matsuura@med.nagoya-cu.ac.jp.
- Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
- Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
- Department of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.
Zitieren
APA
Sato, R., Suzuki, T., Matsuura, K., Kato, D., Hayashi, K., Okayama, K., Okumura, F., Sobue, S., Kusakabe, A., Hasegawa, I., Narita, K., Mizoshita, T., Kimura, Y., Kondo, H., Kojima, H., Hayashi, K., Ozasa, A., Kawamura, H., Fujiwara, K., …, & Kataoka, H. (2025). The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis. Oncology. https://doi.org/10.1159/000547264
Vancouver
Sato R, Suzuki T, Matsuura K, Kato D, Hayashi K, Okayama K, et al. The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis. Oncology. 2025. doi:10.1159/000547264
BibTeX
@article{Sato2025,
author = {Sato, Ryo and Suzuki, Takanori and Matsuura, Kentaro and Kato, Daisuke and Hayashi, Katsumi and Okayama, Kohei and Okumura, Fumihiro and Sobue, Satoshi and Kusakabe, Atsunori and Hasegawa, Izumi and Narita, Kiyoto and Mizoshita, Tsutomu and Kimura, Yoshihide and Kondo, Hiromu and Kojima, Hisayo and Hayashi, Kazuki and Ozasa, Atsushi and Kawamura, Hayato and Fujiwara, Kei and Nojiri, Shunsuke and Kataoka, Hiromi},
title = {The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis},
journal = {Oncology},
year = {2025},
doi = {10.1159/000547264}
}
EUVIMED